SEC Form 4 · accession 0001209191-16-150139
Karyopharm Therapeutics Inc. · KPTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ran Frenkel
Officer — Chief Dev Operations Officer
Period of report
Nov 14, 2016
Accepted (ET)
Nov 15, 2016 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001503802
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Nov 14, 2016 | S | 3,309 | $10.0593 | D | 14,691 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.
- F2Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.05 to $10.13, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.